Results 51 to 60 of about 411,617 (199)
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.The comparative pharmacology and cardiometabolic outcomes of semaglutide, liraglutide and tirzepatide, integrating evidence from major clinical trial programs and meta‐analyses. ABSTRACT Background Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges.
Hiba Bawadi +4 more
wiley +1 more source
JIMD Reports, Volume 67, Issue 5, September 2026.ABSTRACT Fructose‐1,6‐bisphosphatase deficiency is a rare inherited metabolic disorder of gluconeogenesis characterized by recurrent hypoglycemia and lactic acidosis, typically triggered by inadequate glucose intake or increased consumption of fructose, sucrose, or sorbitol.
Raashda A. Sulaiman +6 more
wiley +1 more source
From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity
Obesity, Volume 34, Issue 9, Page 1708-1717, September 2026.ABSTRACT An international panel of experts from the U.S. and China convened to discuss the 2026 TOS–OMA–OAC Expert Guidance Statement on the Pharmacological Management of Obesity, focusing on emerging evidence, regional considerations, and challenges in translating recommendations into long‐term care.
Hong Chen +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7705-7718, September 2026.ABSTRACT Gestational diabetes mellitus (GDM) represents far more than a transient glycaemic disorder: it is a sentinel metabolic event that unveils pre‐existing defects in β‐cell function and insulin action, with profound implications for both maternal and offspring cardiometabolic health across the lifespan.
Mustafa Kanat +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8515-8522, September 2026.ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek +5 more
wiley +1 more source
Insulin degludec: Overview of a novel ultra long-acting basal insulin
, 2013 All the basal insulin products currently available have suboptimal pharmacokinetic (PK) properties, with none reliably providing a reproducible and peakless pharmacodynamic (PD) effect that endures over 24 h from once-daily dosing.
Harris, S +5 more
core +1 more source
International Journal of Endocrinology, 2015 The aim of this study was to investigate the efficacy of insulin degludec used for basal-bolus insulin regimen after switching from twice-daily basal insulin in Japanese patients with type 1 diabetes mellitus.
Yuka Tosaka +14 more
doaj +1 more source
Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8523-8532, September 2026.ABSTRACT Aims To investigate glucose levels and hypoglycaemia risk during exercise or fasting in adults with type 2 diabetes (T2D) treated with once‐weekly basal insulin icodec. Materials and Methods Thirty basal insulin‐treated, physically active individuals with T2D (18–75 years, glycated haemoglobin ≤ 75 mmol/mol, peak oxygen uptake > 20 mL/kg/min ...
Thomas R. Pieber +10 more
wiley +1 more source